Cannabinoid Compositions
Compositions for administering cannabinoid, including edible forms of cannabinoids. Phospholipids and waxes may be used to control the onset timing of cannabis drug effects.
1 . A composition for administering cannabinoid, comprising:
phospholipids;
D-limonene;
polyoxyl 40 hydrogenated castor oil; and
delta-9-tetrahydrocannabinol.
2 . The composition of claim 1 , wherein the composition comprises the following percentages by weight:
at least 14.0% phospholipids;
at least 2.0% D-limonene;
at least 12.0% polyoxyl 40 hydrogenated castor oil; and
at least 1.0% delta-9-tetrahydrocannabinol.
3 . The composition of claim 2 , wherein the phospholipids comprise phosphatidylcholine and phosphatidylethanolamine.
4 . The composition of claim 3 , wherein the phospholipids are comprised of at least 85% phosphatidylcholine.
5 . The composition of claim 3 further comprising approximately 16% by weight of medium chain triglyceride oil
6 . The composition of claim 5 further comprising approximately 55% by weight of polyethylene glycol 300.
7 . The composition of claim 1 , wherein the composition comprises approximately the following percentages by weight:
approximately 21.0% phospholipids;
approximately 7.0% D-limonene;
approximately 70.0% polyoxyl 40 hydrogenated castor oil; and
approximately 1.0% delta-9-tetrahydrocannabinol.
8 . The composition of claim 7 , wherein the phospholipids comprise phosphatidylcholine and phosphatidylethanolamine.
9 . The composition of claim 9 , wherein the phospholipids are comprised of at least 75% phosphatidylcholine.
10 . The composition of claim 9 , wherein the phospholipids are comprised of at least 90% phosphatidylcholine.
11 . A composition for administering cannabinoid, comprising approximately the following percentages by weight:
8.0% lecithin fraction enriched with phospholipids;
8.0% vitamin E;
0.4% lemon oil;
75.3% glycerin; and
8.3% ethanol.
12 . The composition of claim 11 wherein the phospholipids are comprised of at least 50% Phosphatidylcholine.
13 . The composition of claim 12 further comprising 10 milligrams of delta-9-tetrahydrocannabinol.
14 . The composition of claim 13 , wherein the composition comprises 20 moles of lecithin fraction enriched with at least 85% phosphatidylcholine for each mole of delta-9-tetrahydrocannabinol.
15 . The composition of claim 11 wherein the phospholipids are comprised of at least 85% phosphatidylcholine.
16 . The composition of claim 15 further comprising 10 milligrams of delta-9-tetrahydrocannabinol.
17 . The composition of claim 16 , wherein the composition comprises 20 moles of lecithin fraction enriched with at least 85% phosphatidylcholine for each mole of delta-9-tetrahydrocannabinol.
18 . A composition for administering cannabinoid, comprising approximately the following percentages by weight:
26% lecithin fraction enriched with phospholipids;
26% vitamin E TPGS;
12% polysorbate 80;
5% cannabinoids; and
31% ethanol.
19 . The composition of claim 19 wherein the phospholipids are comprised of at least 50% phosphatidylcholine.
20 . The composition of claim 19 wherein the phospholipids are comprised of at least 85% phosphatidylcholine.